Syntis

Creating a New Class of Therapy

[Syntis @SyntisBio]

We're excited to share new Phase 1/1b single ascending dose data showing SYNT-101 was well tolerated at every dose, with no serious adverse events or discontinuations. Join CDO David Rosenbaum at the Obesity & Weight Loss Drug Development Summit in Boston: https://t.co/9Pv4u8Akua

[Syntis @SyntisBio]

We're heading to Boston for the 4th Annual Obesity & Weight Loss Drug Development Summit. Our CDO, David Rosenbaum, will take the stage on July 16 to share how we are replicating the "gold standard" by mimicking gastric bypass through a once-daily pill. https://t.co/x3SlYCx8x4.

[Syntis @SyntisBio]

We're thrilled to welcome Matt Dallas as our new CFO. With 25+ years of life sciences finance expertise spanning IPOs, partnerships & scaling ops, he's the perfect addition as we advance SYNT-101 and our #obesity pipeline. Welcome to the team, Matt! https://t.co/TxGTtfnvIV

[Syntis @SyntisBio]

Today, we shared that the first participant has been dosed in the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101 for #obesity, as well as key new additions to our executive team. Read more here: https://t.co/eR4HIybnNg

[Syntis @SyntisBio]

Today we announce a $38 million financing, including a $33M Series A led by Cerberus Ventures. This is an exciting moment for Syntis, accelerating our vision to revolutionize both chronic and #raredisease treatment through safe, effective oral therapies. https://t.co/SwbIzYotU8

[WIRED @WIRED]

A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an alternative to surgeries and GLP-1 drugs. https://t.co/R4UsCWYthz

[WIRED Science @WIREDScience]

A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an alternative to surgeries and GLP-1 drugs. https://t.co/lr994NZaVM

[Syntis @SyntisBio]

Today we announced positive preclinical and first-in-human data for our lead candidate, SYNT-101, an investigational once-daily oral treatment for #obesity at the European Congress on Obesity and Weight Management. Read more: https://t.co/9LdK8MN8Ai

[BioSpace @biospace]

Seeking to carve out its own niche in the obesity space, @SyntisBio launched on Tuesday to develop an oral weight-loss treatment that mimics the effects of gastric bypass surgery.
#pharma #biospace
https://t.co/blXCzRDKxO

[BioWorld @BioWorld]

.@SyntisBio launches for oral obesity, rare disease drugs https://t.co/KAV7XAb1Jj #biotech #pharma

[Syntis @SyntisBio]

Today, we launch to revolutionize oral therapy for obesity, diabetes and rare diseases by unlocking the full therapeutic potential of the small intestine! Read more below:
https://t.co/TszHyzBCJG